Therapy Detail

Therapy Name Isatuximab
Therapy Description

Isatuximab (SAR650984) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Isatuximab SAR650984 Isatuximab (SAR650984) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown multiple myeloma not applicable Isatuximab Phase I Actionable In a Phase I trial, Isatuximab (SAR650984) treatment resulted in complete response in 6% (2/34), partial response in 18% (6/34), and stable disease in 41% (14/34) of patients with relapsed or refractory multiple myeloma (J Clin Oncol 32:5s, 2014 (suppl; abstr 8532)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01084252 Phase Ib/II Isatuximab Dexamethasone + Isatuximab Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Active, not recruiting
NCT03367819 Phase Ib/II Isatuximab Isatuximab + REGN2810 Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Recruiting
NCT02999633 Phase II Isatuximab Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY) Terminated
NCT03637764 Phase Ib/II Atezolizumab + Isatuximab Isatuximab Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Recruiting
NCT02514668 Phase I Isatuximab A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma Recruiting